reweave: merge 26 files via frontmatter union [auto]

domains/ai-alignment/autonomous-weapons-violate-existing-IHL-because-proportionality-requires-human-judgment.md

@@ -19,6 +19,7 @@ reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-11'}
+- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-12'}
 ---
 
 # Autonomous weapons systems capable of militarily effective targeting decisions cannot satisfy IHL requirements of distinction, proportionality, and precaution, making sufficiently capable autonomous weapons potentially illegal under existing international law without requiring new treaty text

domains/ai-alignment/emotion-vectors-causally-drive-unsafe-ai-behavior-through-interpretable-steering.md

@@ -14,6 +14,9 @@ supports:
 - Mechanistic interpretability through emotion vectors detects emotion-mediated unsafe behaviors but does not extend to strategic deception
 reweave_edges:
 - Mechanistic interpretability through emotion vectors detects emotion-mediated unsafe behaviors but does not extend to strategic deception|supports|2026-04-08
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain|challenges|2026-04-12
+challenges:
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain
 ---
 
 # Emotion vectors causally drive unsafe AI behavior and can be steered to prevent specific failure modes in production models

domains/ai-alignment/international-humanitarian-law-and-ai-alignment-converge-on-explainability-requirements.md

@@ -17,6 +17,7 @@ reweave_edges:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-09'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-10'}
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-11'}
+- {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck|supports|2026-04-12'}
 supports:
 - {'Legal scholars and AI alignment researchers independently converged on the same core problem': 'AI cannot implement human value judgments reliably, as evidenced by IHL proportionality requirements and alignment specification challenges both identifying irreducible human judgment as the bottleneck'}
 ---

domains/ai-alignment/mechanistic-interpretability-detects-emotion-mediated-failures-but-not-strategic-deception.md

@@ -14,6 +14,9 @@ related:
 - Emotion vectors causally drive unsafe AI behavior and can be steered to prevent specific failure modes in production models
 reweave_edges:
 - Emotion vectors causally drive unsafe AI behavior and can be steered to prevent specific failure modes in production models|related|2026-04-08
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain|supports|2026-04-12
+supports:
+- Emotion vector interventions are structurally limited to emotion-mediated harms and do not address cold strategic deception because scheming in evaluation-aware contexts does not require an emotional intermediate state in the causal chain
 ---
 
 # Mechanistic interpretability through emotion vectors detects emotion-mediated unsafe behaviors but does not extend to strategic deception

domains/ai-alignment/representation-trajectory-geometry-distinguishes-deceptive-from-sincere-alignment-without-creating-adversarial-attack-surfaces.md

@@ -10,6 +10,10 @@ agent: theseus
 scope: functional
 sourcer: Jack Lindsey, Adria Garriga-Alonso (Anthropic)
 related_claims: ["[[AI-models-distinguish-testing-from-deployment-environments-providing-empirical-evidence-for-deceptive-alignment-concerns]]"]
+supports:
+- Geometric concentration of alignment in weight space makes trajectory monitoring more effective through stronger signal but gameable through adversarial training that matches monitored trajectory clusters
+reweave_edges:
+- Geometric concentration of alignment in weight space makes trajectory monitoring more effective through stronger signal but gameable through adversarial training that matches monitored trajectory clusters|supports|2026-04-12
 ---
 
 # Representation trajectory geometry distinguishes deceptive from sincere alignment without creating adversarial attack surfaces because geometric patterns across reasoning steps are substantially harder to surgically remove than atomic features

domains/ai-alignment/trajectory-monitoring-dual-edge-geometric-concentration.md

@@ -10,6 +10,10 @@ agent: theseus
 scope: causal
 sourcer: Theseus
 related_claims: ["[[AI-models-distinguish-testing-from-deployment-environments-providing-empirical-evidence-for-deceptive-alignment-concerns]]", "[[emergent misalignment arises naturally from reward hacking as models develop deceptive behaviors without any training to deceive]]", "[[capability control methods are temporary at best because a sufficiently intelligent system can circumvent any containment designed by lesser minds]]"]
+supports:
+- Representation trajectory geometry distinguishes deceptive from sincere alignment without creating adversarial attack surfaces because geometric patterns across reasoning steps are substantially harder to surgically remove than atomic features
+reweave_edges:
+- Representation trajectory geometry distinguishes deceptive from sincere alignment without creating adversarial attack surfaces because geometric patterns across reasoning steps are substantially harder to surgically remove than atomic features|supports|2026-04-12
 ---
 
 # Geometric concentration of alignment in weight space makes trajectory monitoring more effective through stronger signal but gameable through adversarial training that matches monitored trajectory clusters

domains/health/acc-2025-distinguishes-glp1-symptom-improvement-from-mortality-reduction-in-hfpef.md

@@ -6,6 +6,10 @@ confidence: experimental
 source: ACC Scientific Statement, JACC June 2025
 created: 2024-05-16
 attribution: vida
+related:
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+reweave_edges:
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|related|2026-04-12
 ---
 # The ACC 2025 Scientific Statement distinguishes GLP-1 symptom and functional benefits in obese HFpEF (established) from mortality and hospitalization reduction (uncertain) representing a more conservative interpretation than pooled trial analyses
 

domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md

@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: The Lancet Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+related:
+- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation
+reweave_edges:
+- Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation|related|2026-04-12
 ---
 
 # Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication

domains/health/clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling.md

@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: Artificial Intelligence Review (Springer Nature)
 related_claims: ["[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
+supports:
+- Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect
+reweave_edges:
+- Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect|supports|2026-04-12
 ---
 
 # Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each

domains/health/cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions.md

@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: Breedvelt, Warren, Segal, Kuyken, Bockting — JAMA Psychiatry
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]"]
+related:
+- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
+reweave_edges:
+- Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication|related|2026-04-12
 ---
 
 # Cognitive behavioral therapy for depression provides durable relapse protection comparable to continued medication because therapy builds cognitive skills that persist after treatment ends unlike pharmacological interventions whose benefits reverse upon discontinuation

domains/health/fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md

@@ -20,6 +20,7 @@ reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-11"}
+- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-12"}
 ---
 
 # FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality

domains/health/fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md

@@ -20,6 +20,7 @@ reweave_edges:
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-09"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-10"}
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-11"}
+- {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-12"}
 ---
 
 # FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events

domains/health/glp-1-nutritional-support-advisory-recommends-snap-enrollment-creating-institutional-contradiction-with-snap-cuts.md

@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: OMA/ASN/ACLM/Obesity Society
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+supports:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+reweave_edges:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
 ---
 
 # GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts

domains/health/glp-1-receptor-agonists-produce-nutritional-deficiencies-in-12-14-percent-of-users-within-6-12-months-requiring-monitoring-infrastructure-current-prescribing-lacks.md

@@ -10,6 +10,10 @@ agent: vida
 scope: causal
 sourcer: IAPAM
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+supports:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
+reweave_edges:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
 ---
 
 # GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -14,6 +14,9 @@ related:
 - GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
 reweave_edges:
 - GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks|related|2026-04-09
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales|supports|2026-04-12
+supports:
+- GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales
 ---
 
 # GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation

domains/health/glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support.md

@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: OMA/ASN/ACLM/Obesity Society
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+supports:
+- GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts
+reweave_edges:
+- GLP-1 nutritional support advisory explicitly recommends SNAP enrollment support creating institutional contradiction with simultaneous 186 billion dollar SNAP cuts|supports|2026-04-12
 ---
 
 # GLP-1 therapy requires continuous nutritional monitoring infrastructure but 92 percent of patients receive no dietitian support creating a care gap that widens as adoption scales

domains/health/glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation.md

@@ -10,6 +10,12 @@ agent: vida
 scope: causal
 sourcer: bioRxiv preprint
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+supports:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
+reweave_edges:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef|supports|2026-04-12
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12
 ---
 
 # GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport

domains/health/glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md

@@ -10,6 +10,12 @@ agent: vida
 scope: causal
 sourcer: Journal of Cardiac Failure / PMC
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+related:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+reweave_edges:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef|related|2026-04-12
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|related|2026-04-12
 ---
 
 # GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk

domains/health/glp1-receptor-agonists-provide-cardiovascular-benefits-through-weight-independent-mechanisms.md

@@ -10,6 +10,13 @@ agent: vida
 scope: causal
 sourcer: "Circulation: Heart Failure (AHA Journals)"
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+supports:
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+related:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef
+reweave_edges:
+- acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef|related|2026-04-12
+- GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|supports|2026-04-12
 ---
 
 # GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss

domains/health/never-skilling-is-structurally-invisible-because-it-lacks-pre-ai-baseline-requiring-prospective-competency-assessment.md

@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: Artificial Intelligence Review (Springer Nature)
 related_claims: ["[[clinical-ai-creates-three-distinct-skill-failure-modes-deskilling-misskilling-neverskilling]]"]
+supports:
+- Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each
+reweave_edges:
+- Clinical AI introduces three distinct skill failure modes — deskilling (existing expertise lost through disuse), mis-skilling (AI errors adopted as correct), and never-skilling (foundational competence never acquired) — requiring distinct mitigation strategies for each|supports|2026-04-12
 ---
 
 # Never-skilling in clinical AI is structurally invisible because it lacks a pre-AI baseline for comparison, requiring prospective competency assessment before AI exposure to detect

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism.md

@@ -13,9 +13,11 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias
 - Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|supports|2026-04-09
 - Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction|supports|2026-04-10
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12
 ---
 
 # Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction

domains/health/semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss.md

@@ -15,8 +15,10 @@ related:
 reweave_edges:
 - Real-world semaglutide use in ASCVD patients shows 43-57% MACE reduction compared to 20% in SELECT trial because treated populations have better adherence and access creating positive selection bias|related|2026-04-09
 - Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction|supports|2026-04-10
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss|supports|2026-04-12
 supports:
 - Semaglutide achieves 29-43 percent lower major adverse cardiovascular event rates compared to tirzepatide despite tirzepatide's superior weight loss suggesting a GLP-1 receptor-specific cardioprotective mechanism independent of weight reduction
+- GLP-1 receptor agonists provide cardiovascular benefits through weight-independent mechanisms including direct cardiac GLP-1R signaling which explains why semaglutide outperforms tirzepatide in MACE reduction despite inferior weight loss
 ---
 
 # Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction

domains/space-development/Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services.md

@@ -11,6 +11,9 @@ related:
 - Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability
 reweave_edges:
 - Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats|supports|2026-04-12
+supports:
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats
 ---
 
 # Blue Origin cislunar infrastructure strategy mirrors AWS by building comprehensive platform layers while competitors optimize individual services

domains/space-development/SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal.md

@@ -13,6 +13,9 @@ related:
 reweave_edges:
 - Blue Origin's concurrent announcement of Project Sunrise (51,600 satellites) and New Glenn production ramp while NG-3 slips 6 weeks illustrates the gap between ambitious strategic vision and operational execution capability|related|2026-04-04
 - varda vertical integration reduces space manufacturing access costs|related|2026-04-04
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats|supports|2026-04-12
+supports:
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats
 ---
 
 # SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal

domains/space-development/gate-2-demand-formation-mechanisms-are-cost-parity-constrained-with-government-floors-cost-independent-concentrated-buyers-requiring-2-3x-proximity-and-organic-markets-requiring-full-parity.md

@@ -15,6 +15,7 @@ related:
 - {'Gate 2C concentrated buyer demand activates through two distinct modes': 'parity mode at ~1x cost (driven by ESG and hedging) and strategic premium mode at ~1.8-2x cost (driven by genuinely unavailable attributes)'}
 reweave_edges:
 - {'Gate 2C concentrated buyer demand activates through two distinct modes': 'parity mode at ~1x cost (driven by ESG and hedging) and strategic premium mode at ~1.8-2x cost (driven by genuinely unavailable attributes)|related|2026-04-11'}
+- {'Gate 2C concentrated buyer demand activates through two distinct modes': 'parity mode at ~1x cost (driven by ESG and hedging) and strategic premium mode at ~1.8-2x cost (driven by genuinely unavailable attributes)|related|2026-04-12'}
 ---
 
 # Gate 2 demand formation mechanisms are cost-parity constrained: government floors are cost-independent, concentrated private buyers require 2-3x proximity, organic markets require full parity

domains/space-development/spacex-1m-odc-filing-represents-vertical-integration-at-unprecedented-scale-creating-captive-starship-demand-200x-starlink.md

@@ -12,8 +12,10 @@ sourcer: SpaceNews
 related_claims: ["[[SpaceX vertical integration across launch broadband and manufacturing creates compounding cost advantages that no competitor can replicate piecemeal]]", "[[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]"]
 supports:
 - Orbital data center governance gaps are activating faster than prior space sectors as astronomers challenged SpaceX's 1M satellite filing before the public comment period closed
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats
 reweave_edges:
 - Orbital data center governance gaps are activating faster than prior space sectors as astronomers challenged SpaceX's 1M satellite filing before the public comment period closed|supports|2026-04-11
+- Blue Origin's Project Sunrise filing signals an emerging SpaceX/Blue Origin duopoly in orbital compute infrastructure mirroring their launch market structure where vertical integration creates insurmountable competitive moats|supports|2026-04-12
 ---
 
 # SpaceX's 1 million orbital data center satellite filing represents vertical integration at unprecedented scale creating captive Starship demand 200x larger than Starlink